New Zealand markets close in 6 hours 3 minutes

Intercept Pharmaceuticals, Inc. (ICPT)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
14.91+0.67 (+4.71%)
At close: 04:00PM EST
14.68 -0.23 (-1.54%)
After hours: 04:21PM EST
Currency in USD

Valuation measures4

Market cap (intra-day) 611.73M
Enterprise value 453.19M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)1.20
Price/book (mrq)5.68
Enterprise value/revenue 1.19
Enterprise value/EBITDA -3.62

Trading information

Stock price history

Beta (5Y monthly) 1.13
52-week change 3-10.21%
S&P500 52-week change 3-12.31%
52-week high 321.25
52-week low 310.81
50-day moving average 314.68
200-day moving average 315.61

Share statistics

Avg vol (3-month) 3855.36k
Avg vol (10-day) 3424.36k
Shares outstanding 541.42M
Implied shares outstanding 6N/A
Float 833.99M
% held by insiders 13.20%
% held by institutions 181.55%
Shares short (14 Nov 2022) 43.98M
Short ratio (14 Nov 2022) 45.29
Short % of float (14 Nov 2022) 412.18%
Short % of shares outstanding (14 Nov 2022) 49.62%
Shares short (prior month 13 Oct 2022) 44.02M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)29 Sept 2022

Profitability

Profit margin 54.33%
Operating margin (ttm)-8.98%

Management effectiveness

Return on assets (ttm)-3.94%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)379.84M
Revenue per share (ttm)12.32
Quarterly revenue growth (yoy)16.40%
Gross profit (ttm)360.37M
EBITDA -33.05M
Net income avi to common (ttm)-157.46M
Diluted EPS (ttm)-2.20
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)490.85M
Total cash per share (mrq)11.85
Total debt (mrq)339.6M
Total debt/equity (mrq)315.39
Current ratio (mrq)2.46
Book value per share (mrq)2.60

Cash flow statement

Operating cash flow (ttm)-17.37M
Levered free cash flow (ttm)-6.31M